Targeting Tankyrase 2 for Wnt Pathway Inhibition: Market Intelligence, Clinical Progress, and High-Purity Reagents for Colorectal Cancer & Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNKS2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNKS2 Recombinant Protein (Full-Length & Catalytic Domain) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Active enzyme suitable for PARylation assays. |
View TNKS2 Products |
| Gene Delivery | TNKS2 Lentivirus Particles (ORF) Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. |
View TNKS2 Products |
| Benchmark Ab | Anti-TNKS2 Antibody (Recombinant Rabbit mAb) Sequence-verified detection antibody for Western/IP. High specificity, no cross-reactivity with TNKS1. |
View TNKS2 Products |
| Validator | TNKS2 siRNA Set (3 target-specific + 1 control) For knockdown verification and specificity controls in cell-based assays. |
View TNKS2 Products |
| Related Target A | TNKS1 (Tankyrase 1) High-homology isozyme (85% catalytic domain identity). Essential for selectivity profiling. |
View TNKS1 Products |
| Related Target B | AXIN1 Direct PARsylation substrate; scaffold protein for Wnt destruction complex. Cell-based assay endpoint. |
View AXIN1 Products |
| Off-Target Control | PARP1 (Catalytic Domain) Counter-screening target to assess selectivity vs. DNA repair PARPs. |
View PARP1 Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isozyme Selectivity (TNKS2 vs TNKS1) | Human TNKS1 & TNKS2 proteins available as matched pair (>95% purity, Mass Spec verified) for side-by-side IC50 determination |
| PARP Family Off-target Screening | PARP1/PARP2 catalytic domain proteins strictly verified by sequence for selectivity counter-screens |
| Catalytic Integrity (SAM-dependent oligomerization) | Full-length proteins expressed in HEK293 ensuring native post-translational modifications and proper SAM domain folding required for activity |
| Drug Resistance Profiling | Mutant panel available (e.g., H1030A catalytic dead, G1031W SAM domain mutants) for mechanism of resistance studies |
| Cellular Target Engagement | TNKS2-specific Lentivirus for stable overexpression; TNKS2 siRNA for loss-of-function validation in AXIN1 stabilization assays |
| Lack of Controls | Clinical Benchmark Antibodies included for target engagement confirmation |
| False Positives | Validated siRNA included for specificity checks in cellular PARylation and AXIN stabilization assays |
Live TNKS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Tankyrase Inhibitor Trials (General)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for Tankyrase inhibitors is intensifying, with major players shifting focus from broad PARP inhibitors to TNKS1/2-selective small molecules targeting the Wnt/β-catenin pathway. As first-generation compounds (e.g., G007-LK, NVP-TNKS656) face pharmacokinetic and toxicity challenges (notably GI toxicity from Wnt inhibition), the next wave of R&D is targeting PROTAC-based degraders and allosteric inhibitors to improve the therapeutic window. The field is pivoting toward biomarker-driven development (APC-mutant colorectal cancer) and combination strategies with immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Astellas (G007-LK), Novartis (NVP-TNKS656), BMS (BMS-986115) | Colorectal Cancer, Desmoid Tumors | Enzymatic Assay (Active TNKS2 required), TNKS1 Selectivity Panel |
| PROTAC Degrader | Arvinas, Crew Bio (preclinical), Academic labs | APC-mutant Solid Tumors | Cell-based Degradation Assay (Lentivirus-stable lines needed) |
| Dual TNKS1/2 Inhibitor | Eisai, Others | Familial Adenomatous Polyposis (FAP) | Homolog Panel Screening (Both TNKS1 & TNKS2 proteins) |
| Allosteric Modulator | Early stage biotechs | Solid Tumors | Conformational Binding Assay (Full-length protein with SAM domain) |